Cartalax Peptide 20mg – Protide Health USA

Cartalax Overview & Technical Specifications

Cartalax is a synthetic bioregulatory tripeptide composed of three amino acids:

Ala-Glu-Asp

or:

AED

The complete terminal representation is:

H-Ala-Glu-Asp-OH

Protide Health supplies Cartalax peptide as 20mg of 99% purity, HPLC-MS verified, third-party tested lyophilized research material in a 3mL vial.

Cartalax is commonly discussed in peptide-bioregulator research involving:

• Chondrocytes
• Cartilage extracellular matrix
• Age-associated cellular signaling
• Peptide regulation
• Cellular proliferation and apoptosis pathways
• Experimental osteoarthritis models

Technical Specifications

• Product Name: Cartalax
• Chemical Name: Alanyl-glutamyl-aspartic acid
• Alternative Names: Ala-Glu-Asp, AED, Cartalax peptide
• Quantity: 20mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Type: Synthetic bioregulatory tripeptide
• Peptide Length: 3 amino acids
• Sequence: Ala-Glu-Asp
• Terminal Representation: H-Ala-Glu-Asp-OH
• Molecular Formula: C12H19N3O8
• Molecular Weight: approximately 333.29 g/mol
• PubChem CID: 87815447
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: Cartilage, chondrocyte, cellular-aging, extracellular-matrix, biochemical, analytical, and qualified preclinical research only

PubChem identifies Cartalax/AED as a synthetic tripeptide with the sequence Ala-Glu-Asp and molecular weight of approximately 333.29 g/mol.

What Is Cartalax?

The phrase what is Cartalax generally refers to the short peptide:

Ala-Glu-Asp

Cartalax belongs to a class of compounds often described in the literature as short peptide bioregulators.

These peptides are studied for potential effects on cellular signaling, gene expression, differentiation, proliferation, and tissue-specific regulatory pathways.

Cartalax research has focused particularly on:

• Chondrocyte biology
• Cartilage aging
• Osteoarthritis-associated pathways
• Extracellular-matrix turnover
• Senescence-associated signaling

This research positioning does not establish Cartalax as a human cartilage treatment.

Cartalax Peptide & Chondrocyte Research

A central area of Cartalax peptide research involves chondrocytes.

Chondrocytes are the primary cellular component of cartilage and are responsible for maintaining extracellular-matrix molecules such as:

• Type II collagen
• Aggrecan
• Proteoglycans
• Other cartilage-associated matrix components

With aging and osteoarthritis, chondrocytes can develop altered secretory and metabolic phenotypes.

A 2023 review specifically discussed AED/Cartalax in the context of aging-associated chondrocyte secretory phenotype and peptide bioregulation.

Cartalax & Cartilage Aging Research

Cartilage aging involves multiple interconnected processes, including:

• Reduced matrix synthesis
• Increased matrix degradation
• Altered cytokine production
• Cellular senescence
• Oxidative stress
• Changes in protease activity
• Chondrocyte dysfunction

Cartalax has been discussed as a research peptide in models examining these age-associated processes.

The strongest published claims remain concentrated in:

• Animal models
• Cellular research
• Small or regionally reported clinical observations
• Review literature on peptide bioregulation

This means the evidence should be interpreted cautiously.

Cartalax & Extracellular Matrix Research

Cartilage extracellular matrix is composed primarily of:

• Type II collagen
• Proteoglycans
• Glycosaminoglycans
• Matrix-associated proteins

Experimental cartilage research frequently measures:

• Matrix synthesis
• Matrix degradation
• Collagen expression
• Proteoglycan production
• Matrix metalloproteinase activity

Cartalax research has been discussed in relation to regulation of chondrocyte secretory activity and extracellular-matrix homeostasis.

However, broader cartilage-peptide research also demonstrates that effects vary greatly according to peptide sequence and experimental system.

Cartalax Peptide Benefits: Evidence Context

The phrase cartalax peptide benefits commonly appears in consumer searches.

Published Cartalax-related literature has discussed experimental effects involving:

• Chondrocyte signaling
• Cartilage metabolism
• Cellular aging
• Proliferation-associated molecules
• Apoptosis-associated pathways
• Extracellular-matrix regulation

These findings do not establish that Protide Health Cartalax:

• Rebuilds cartilage in humans
• Treats osteoarthritis
• Eliminates joint pain
• Regenerates damaged joints
• Reverses aging
• Prevents cartilage degeneration

The available evidence is not sufficient to support those claims for this research product.

Cartalax & Senescence-Associated Signaling

One area highlighted in recent Cartalax literature is the senescence-associated secretory phenotype, or SASP.

Aging chondrocytes can show changes involving:

• Cytokine secretion
• Matrix degradation
• Sirtuin expression
• Pro-apoptotic signaling
• Proliferative signaling

A 2023 review reported that AED/Cartalax had been studied in animal osteoarthritis models and older patient groups and discussed effects on pro-apoptotic and proliferative molecules associated with chondrocyte SASP.

These findings should be regarded as preliminary and hypothesis-generating rather than definitive clinical evidence.

Cartalax Peptide Dosage Search Context

The phrase cartalax peptide dosage generally concerns human administration.

Protide Health does not provide human dosing instructions.

The 20mg quantity on this product page describes the total amount of research material contained in the vial.

It is not a recommended dose.

No instructions are provided for:

• Human injection
• Oral administration
• Daily dosing
• Treatment cycles
• Joint protocols
• Body-weight calculations
• Reconstitution for administration

Laboratory researchers should establish experimental concentrations using validated study methodology.

Cartalax Dosage Search Context

The phrase cartalax dosage refers to the same human-use intent.

Published human-use reports from peptide-bioregulator literature should not be converted into self-administration instructions for independently supplied research material.

Differences may exist in:

• Product identity
• Purity
• Formulation
• Route
• Manufacturing controls
• Study population
• Monitoring

Protide Health therefore provides no human dosage recommendation.

Cartalax Peptide Protocol Searches

The phrase cartalax peptide protocol usually refers to an administration schedule or treatment regimen.

No human-use protocol is provided here.

For research purposes, a scientifically appropriate experimental protocol should instead define:

• Peptide concentration
• Cell type
• Exposure duration
• Control groups
• Measured endpoints
• Replication
• Statistical analysis

This approach is more appropriate for laboratory investigation than adopting consumer administration protocols.

Cartalax Peptide Side Effects Search Context

The phrase cartalax peptide side effects reflects interest in human safety.

A comprehensive modern human safety profile for research-grade Cartalax has not been established.

Limitations include:

• Limited large-scale clinical evidence
• Limited independent replication
• Incomplete long-term safety data
• Variability between research and commercial formulations
• Limited regulatory-standard pharmacovigilance data

For these reasons, Protide Health does not claim that Cartalax is safe for human administration.

Cartalax Reddit Search Context

The keyword cartalax reddit generally refers to user-generated discussions, anecdotal experiences, and informal product reviews.

Reddit discussions may contain:

• Personal experiences
• Unverified dosing claims
• Product-source recommendations
• Subjective outcomes
• Unsupported safety claims

These should not be treated as scientific evidence.

For Cartalax research, stronger evidence sources include:

• PubMed-indexed literature
• Peer-reviewed experimental studies
• Verified analytical data
• Controlled laboratory models

Anecdotal online reports cannot establish efficacy or safety.

Cartalax for Sale: Laboratory Sourcing Context

The phrase cartalax for sale has transactional search intent.

For qualified laboratory sourcing, researchers should evaluate:

• Correct sequence
• Molecular identity
• Defined purity
• HPLC-MS verification
• Third-party testing
• Storage conditions
• Research-only labeling
• Analytical traceability

Protide Health supplies Cartalax peptide exclusively as laboratory research material.

It is not sold as a joint treatment, anti-aging therapy, medication, or human supplement.

Cartalax & Ala-Glu-Asp Chemistry

Cartalax is a short linear peptide composed of:

1. Alanine
2. Glutamic acid
3. Aspartic acid

This gives the sequence:

Ala-Glu-Asp

Its small molecular size distinguishes it from larger peptide hormones and growth factors.

PubChem lists the molecular formula as:

C12H19N3O8

with molecular weight:

333.29 g/mol.

Cartalax & Short Peptide Bioregulator Research

Short peptide bioregulator research proposes that small peptides can influence cellular regulatory pathways.

Experimental literature involving other short peptides has explored:

• Nuclear localization
• Histone interactions
• Gene-expression regulation
• Chromatin organization
• Cellular differentiation

However, findings involving other peptides should not automatically be attributed to Cartalax.

Sequence specificity is important.

For example, studies examining other short bioregulators demonstrate sequence-dependent interactions with cellular targets.

Cartalax vs General Cartilage Peptides

Cartalax should not be confused with all cartilage-active peptides.

Cartilage research includes many unrelated peptide systems, including:

• Matrix-derived peptides
• Growth-factor-binding peptides
• Integrin-associated peptides
• Chondrogenic scaffold peptides
• Cartilage-targeting peptides

Recent reviews emphasize that cartilage-directed peptides can act through highly different mechanisms.

Cartalax should therefore be evaluated according to its own sequence and evidence base.

Related Protide Health Research Products

Researchers comparing other short bioregulatory peptides may review Crystagen 20mg for a distinct peptide-bioregulator research model.

The N-Acetyl Epithalon research peptide provides a chemically different modified short-peptide system.

Researchers may also examine Vesugen 20mg for another distinct bioregulatory peptide research model.

These products should not be treated as chemically or mechanistically interchangeable with Cartalax.

Research Applications

Qualified laboratories may investigate Cartalax peptide in research involving:

• Chondrocyte biology
• Cartilage aging
• Extracellular-matrix regulation
• Cellular senescence
• SASP-associated pathways
• Peptide bioregulation
• Cellular proliferation
• Apoptosis-associated pathways
• Peptide analytical characterization
• Comparative short-peptide research

Study design should use appropriate controls and independently verified analytical methods.

Research Format & Storage

Protide Health supplies Cartalax as:

• Quantity: 20mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified
• Verification: Third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water

Storage specifications:

• Store at ≤6°C
• Keep sealed
• Protect from heat
• Protect from direct light
• Protect from moisture

These conditions describe laboratory storage only.

Research Limitations

Several limitations should be considered when interpreting Cartalax research:

• Cartalax research has a relatively narrow evidence base.
• Much of the literature comes from peptide-bioregulator research programs.
• Independent replication is limited.
• Large randomized clinical trials are lacking.
• Animal findings do not establish equivalent human effects.
• Chondrocyte findings do not establish cartilage regeneration in humans.
• Osteoarthritis-related findings remain preliminary.
• Research involving other short peptides cannot automatically be attributed to Cartalax.
• Reddit and other anecdotal reports are not controlled evidence.
• The 20mg quantity represents vial contents rather than a human dose.
• The Protide Health product is not an FDA-approved pharmaceutical product.

For these reasons, Cartalax peptide is supplied strictly for qualified laboratory research.

Literature & Citation Index

Chondrocytes Secretory Phenotype Associated With Aging: Role in Osteoarthritis and Prospects for Peptide Bioregulation

Year: 2023
PMID: 37782637
Research Context: Chondrocyte aging, SASP, extracellular matrix, cartilage degeneration, AED/Cartalax, animal osteoarthritis models, and peptide bioregulation.

Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis

Year: 2024
PMID: 39291443
Research Context: Chondroinductive peptides, cartilage matrix, tissue engineering, peptide design, chondrogenesis, and preclinical cartilage research.

Peptide-Based Biomaterials for Bone and Cartilage Regeneration

Year: 2024
PMID: 38397915
Research Context: Peptide systems, cartilage regeneration, osteochondral tissue engineering, cellular differentiation, and extracellular-matrix research.

Researchers can review broader Cartalax, Ala-Glu-Asp, and cartilage peptide research indexed by PubMed for additional peer-reviewed background literature.

Frequently Asked Questions

What is Cartalax?

Cartalax is a synthetic tripeptide composed of Ala-Glu-Asp, also abbreviated AED.

What is Cartalax peptide?

Cartalax peptide is a three-amino-acid bioregulatory peptide investigated mainly in cartilage, chondrocyte, cellular-aging, and peptide-regulation research.

What is the Cartalax sequence?

The sequence is:

Ala-Glu-Asp

or:

AED

What is the molecular formula?

The molecular formula is:

C12H19N3O8

What is the molecular weight?

The molecular weight is approximately:

333.29 g/mol

What is the PubChem CID?

The PubChem identifier is:

CID 87815447

What are Cartalax peptide benefits?

Published literature discusses Cartalax in chondrocyte, cartilage-aging, and peptide-bioregulation research, but these findings do not establish human therapeutic benefits.

What is Cartalax peptide dosage?

Protide Health does not provide human cartalax peptide dosage instructions. The 20mg quantity describes total vial contents only.

What is the Cartalax dosage?

No human cartalax dosage is provided. Laboratory researchers should determine experimental concentrations using validated study design.

Is there a Cartalax peptide protocol?

Protide Health does not provide a human cartalax peptide protocol. Experimental protocols should instead be based on defined laboratory endpoints and appropriate controls.

What are Cartalax peptide side effects?

A comprehensive human safety profile for research-grade Cartalax has not been established, so Protide Health does not make human safety claims.

Is Cartalax Reddit information reliable?

Cartalax Reddit discussions are anecdotal and should not be treated as controlled scientific evidence.

Is Cartalax for sale for human use?

No. Although cartalax for sale is a common search phrase, Protide Health supplies Cartalax strictly for qualified laboratory research.

What purity does Protide Health specify?

Protide Health specifies 99% purity, HPLC-MS verification, and third-party testing.

Is Cartalax intended for human use?

No. It is supplied exclusively for cartilage, chondrocyte, cellular-aging, biochemical, molecular, analytical, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This Cartalax product is supplied exclusively for laboratory research, cartilage and chondrocyte studies, extracellular-matrix investigation, cellular-aging research, analytical testing, biochemical experimentation, molecular research, in-vitro studies, and qualified preclinical experimentation.

It is not intended for human or veterinary consumption, osteoarthritis treatment, joint treatment, anti-aging therapy, medical use, injection, oral administration, diagnostic use, therapeutic use, or clinical administration.

No human dosage, injection schedule, oral-use protocol, joint-treatment protocol, Cartalax peptide protocol, body-weight calculation, treatment cycle, or human-use preparation guidance is provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use under applicable institutional, federal, state, and local requirements.

For research use only.